Beam Therapeutics (BEAM) Stock Price, Quote, News & History | Benzinga

Beam Therapeutics Inc (BEAM) Stock Price, Quote, News & History

BEAMNASDAQ

Trade with Public

Trade with Public

$30.48

0.290.96%

At close: Aug 26, 5:00 PM EST

$30.08

-0.11-0.36%

Pre-Market: 7:16 AM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

-

Close

$30.48

Volume / Avg.

22.72K / 2.15M

Day Range

- - -

52 Wk Range

16.02 - 38.26

Market Cap

$3.09B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

56

Short Interest

36.71%

Days to Cover

16.08

Recent Beam Therapeutics Inc. News

Prime Medicine Secures Favorable Arbitration Ruling in Beam Therapeutics Case

Prime Medicine won arbitration with Beam Therapeutics over PM647, avoiding damages and keeping its AATD gene-editing program on track.

Vandana Singh

Powder Keg Stocks: 10 Most‑Shorted Names Primed For A Monster Squeeze (CORRECTED)

Data show high levels of short interest in 10 stocks, including Avis Budget, RH, Lucid and CleanSpark.

Erica Kollmann

Jim Cramer: This Tech Stock Is A 'Winner', Snap Does Not Have Growth

Jim Cramer discussed various stocks on Mad Money Lightning Round. He expressed concerns about Ondas Inc's losses and praised companies like Halliburton and Nokia.

Avi Kapoor

XOMA Royalty, Oruka Therapeutics, Repay Holdings And Other Big Stocks Moving Higher On Monday

U.S. stocks were lower, Dow Jones fell 0.1% on Monday. XOMA shares rose on Ligand's plans to acquire XOMA for $39.00/share. Other big gainers: MANE, ORKA, OGN, XE, PLBL, SLS, ANAB, EVH, IHRT, RPAY, JBIO, BEAM.

Avi Kapoor

Beam Therapeutics Gains On Clinical Update As Gene Therapy Hits Protective Protein Levels

Beam Therapeutics shares rise after BEAM-302 trial data show sustained AAT levels above threshold, supporting accelerated FDA pathway plans.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-359.38M

Investing Cash Flow (TTM)

189.46M

Financing Cash Flow (TTM)

107.69M

Free Cash Flow (TTM)

-372.77M

Capital Expenditure (TTM)

-13.39M

Net Change in Cash (TTM)

-62.23M

Analyst Trends and Forecast

1

Mar

1

May

2

Jul

1

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.5

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$2.24B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

20.19

PB Ratio (TTM)

2.95

Earnings Yield % (TTM)

-2.26%

Earnings Yield % (FWD)

-15.08%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$10.33

Company Debt

Total Debt

$100.26M

LT Debt

$100.26M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$219.83M

Debt to Equity

0.23

Issuance of Debt (TTM)

$93.89M

Repayment of Debt (TTM)

-

Key Statistics

Open

-

Close

$30.48

Volume / Avg.

22.72K / 2.15M

Day Range

- - -

52 Wk Range

16.02 - 38.26

Market Cap

$3.09B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

56

Short Interest

36.71%

Days to Cover

16.08

About

Sector

Health Care

Industry

Biotechnology

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases....

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Beam Therapeutics (BEAM) stock?

A

You can purchase shares of Beam Therapeutics (NASDAQ:BEAM) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Beam Therapeutics (BEAM) competitors?

A

Other companies in Beam Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Beam Therapeutics (BEAM) stock?

A

Beam Therapeutics has a consensus price target of $49.43.

Q

What is the current price for Beam Therapeutics (BEAM)?

A

The stock price for Beam Therapeutics (NASDAQ: BEAM) is $30.08 last updated August 28, 2026 at 7:00 AM EDT.

Q

Does Beam Therapeutics (BEAM) pay a dividend?

A

There are no upcoming dividends for Beam Therapeutics.

Q

When is Beam Therapeutics (NASDAQ:BEAM) reporting earnings?

A

Beam Therapeutics does not have any upcoming earnings scheduled.

Q

Is Beam Therapeutics (BEAM) going to split?

A

There is no upcoming split for Beam Therapeutics.

Q

What sector and industry does Beam Therapeutics (BEAM) operate in?

A

Beam Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.